Abstract Background and Aims Chronic kidney disease (CKD) and acute kidney injury (AKI) are among the most significant long-term complications following radical nephrectomy (RN) for renal masses. In clinical practice, precise renal function assessment is crucial to minimize these risks, particularly for patients with an oncological solitary kidney (SK), where management largely depends on glomerular filtration rate (GFR) values. While estimated GFR (eGFR) is the most commonly

Abstract While modern anticancer therapies have significantly improved survival in patients with cancer, their success is often hindered by unintended side effects and toxicities, particularly to the kidneys. Many conventional chemotherapeutic agents, despite their efficacy, exert nephrotoxic effects that can result in short- and long-term adverse kidney outcomes. This review critically examines the renal implications of non-platinum alkylating agents and other less commonly

Abstract Anticancer therapies have significantly improved survival rates in patients with cancer; however, despite prophylactic measures, many conventional chemotherapeutic agents cause acute and chronic kidney injury. This review provides a comprehensive analysis of the incidence, characteristics, and management of platinum-based and anti-metabolite chemotherapeutic agent-associated nephrotoxicity based on the existing literature. Understanding the profiles of these onconeph

Question: What are the implications of discordancies between estimated glomerular filtration rates (eGFR) derived from serum creatinine...

Scope and consistency of cancer outcomes reported in randomized trials in kidney transplant recipients Eric H. Au, Germaine Wong, Allison...

Srinivasan V, Kfoury B, Ahmad S, Cohen J, Geara AS. Long term outcomes of bevacizumab-associated kidney adverse effects. Journal of...

Cancer Risk and Mortality in Patients With Kidney Disease: A Population-Based Cohort Study Abhijat Kitchlu, Jennifer Reid, Nivethika...

Shruti Gupta , Prakash Gudsoorkar, and Kenar D. Jhaveri Abstract Advances in cancer therapy have significantly improved overall patient...

Transplantation and Cellular Therapy Anthony C. Wood Ariel Perez Perez Brian Arciola Kedar Patel Grace Johnson Elizabeth DiMaggio...

Paul Hanna, Ian Strohbehn, Daiana Moreno1 Destiny Harden, Harish Seethapathy, Shruti Gupta, Meghan Lee, Tianqi Ouyang Matthew Frigault,...

Paul Hanna, Ian Strohbehn, Qiyu Wang, Matthew Frigault, Meghan E Sise For full article: https://www.nature.com/articles/s41409-022-01720-...

Sophia M. Sears, Alexis A. Vega, Zimple Kurlawala, Gabrielle B. Oropilla, Austin Krueger, Parag P. Shah, Mark A. Doll, Robert Miller,...

Mitchell H. Rosner, Kenar D. Jhaveri, Blaithin A. McMahon, Mark A.Perazella Full article link: https://acsjournals.onlinelibrary.wiley.c...

Shruti Gupta, Tiffany Caza, Sandra M. Herrmann, Vipulbhai C. Sakhiya, Kenar D. Jhaveri. For full article: https://pubmed.ncbi.nlm.nih.gov...

off-target ferrochelatase inhibition. Bai Y, Kim JY, Bisunke B, Jayne LA, Silvaroli JA, Balzer MS, Gandhi M, Huang KM, Sander V, Prosek...

Adhikari S, Mamlouk O, Rondon-Berrios H, Workeneh BT. For full article: https://pubmed.ncbi.nlm.nih.gov/34754427/ Abstract Dysregulation...

Gupta S, Short SAP, Sise ME, ICPi-AKI Consortium Investigators, et al. For full article: http://dx.doi.org/10.1136/jitc-2021-003467...